Request Demo
Esperion closes deal for Corstasis Therapeutics’ Enbumyst and CVD franchise
AcquisitionDrug ApprovalAHA
Esperion Therapeutics (Nasdaq: ESPR) has closed its acquisition of Corstasis Therapeutics Inc., a privately held, commercial-stage biopharmaceutical company, adding Enbumyst (bumetanide nasal spray) — the first and only FDA-approved intranasal loop diuretic — to its cardiovascular portfolio. The transaction advances Esperion’s Vision 2040 strategy by extending its cardiometabolic franchise beyond LDL-C management into outpatient fluid management for edema associated with congestive heart failure, hepatic disease, and renal disease including nephrotic syndrome.
As announced earlier this month, Esperion paid USD 75 million upfront and committed to up to USD 180 million in regulatory and commercial milestones, as well as low double-digit royalties on future global sales.
The intranasal formulation is designed to address limitations of oral absorption in patients with fluid overload and reduce reliance on IV diuretics requiring clinic-based administration. The drug was approved by the US FDA in September 2025 for edema associated with heart failure, hepatic disease, and renal disease, and was commercially launched in Q4 2025.
The acquisition allows Esperion to leverage its existing cardiovascular commercial infrastructure to support Enbumyst uptake. The company said it will focus on payer engagement and prescriber education as it expands into outpatient fluid management.
Corstasis also developed earlier-stage subcutaneous bumetanide candidates, RSQ-786 and RSQ-789, extending the platform into additional delivery formats, though timelines for regulatory submission have not been disclosed.
The deal reflects Esperion’s broader strategy to expand beyond LDL-C management into adjacent cardiometabolic indications.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!